FARE is governed by a 9-member operating board known as the Board of Directors. FARE recently introduced two non-voting boards, the Board of Governors and the Board of National Ambassadors, to better position FARE to rapidly respond to the evolving landscape of food allergy and support the organization's growth.
- David G. Bunning, Chair
- John J. Hannan
- Helen Jaffe
- Rebecca Lainovic
- Adam Miller
- Christine Olsen, MD
- Elise Purcell
- Robert L. Rich
- Mary Weiser
- Elliot S. Jaffe, Chairman Emeritus
David G. Bunning
Bunning founded The TLP Group, LLC (TLP) in 2004 and as Chief Executive Officer and Chief Investment Officer has led TLP into a broad range of investments across asset classes in both public and private markets. Prior to founding TLP, Bunning was a Principal, Head of Global Credit Trading at Citadel Investment Group LLC (Citadel) and also a member of the firm’s Management Committee. Bunning joined Citadel in 1991 when the firm’s assets under management were less than $20 million and at the time of Bunning's departure from Citadel in 2004, the firm’s assets under management had reached more than $10 billion.
With the ultimate goal of developing a cure for life-threatening food allergies, Bunning devoted a substantial amount of his time from 2004 through 2013 supporting efforts to develop effective treatments for this disease. Bunning and his family foundation provided funding for research and built collaborative relationships among research leaders at universities across the country, including, Harvard, Stanford, Northwestern, University of Chicago, Duke and Johns Hopkins. Meeting regularly with leaders of the National Institutes of Health (NIH) and with members of Congress, Bunning brought attention to the growing impact of food allergies and the need for increased federal funding for food allergy research. Bunning helped spearhead the inaugural FARE symposium at Harvard Medical School. Now an annual Research Retreat held in the Washington, D.C. area, these symposiums bring together thought leaders in food allergy research, the NIH, the Food and Drug Administration (FDA), the pharmaceutical industry, and patient advocates to develop a coordinated strategy for the treatment of life-threatening food allergies. These events have led to a number of innovative therapeutic developments, some of which are in various stages of FDA review and approval.
Bunning has a B.A. from Harvard College and an MBA from the Booth School of Business at the University of Chicago. He has been an active member of the board of directors for FARE, Ann and Robert H. Lurie Children’s Hospital of Chicago, Ducks Unlimited, and the National Wrestling Coaches Association. Bunning was instrumental in the merger of Food Allergy & Anaphylaxis Network and the Food Allergy Initiative to create FARE. Bunning continues to believe in the positive impact that philanthropy, venture philanthropy, and incubating early stage companies can have to achieve better health outcomes, evidenced by the on-going investments made by both his family foundation and investment firm in early stage biotech and medical device companies that own potentially transformative products or technologies.
The FARE website was my go-to place when my daughter was first diagnosed over a decade ago. Now that her needs have changed, as she has grown, I can see that FARE is in step with those of all ages and stages."